Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure
Status:
Completed
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
HIV-1 infected subjects with CD4 nadir > 200 cells/mm3, no history of virologic failure and
plasma HIV RNA <50 copies/mL for at least 48 weeks while on any United States Department of
Health and Human Services (DHHS) recommended or alternative three-drug antiretroviral regimen
will be randomized to dolutegravir (DTG) plus lamivudine (Arm 1) or continuation of their
current regimen (Arm 2) for 48 weeks. The primary endpoint is virologic failure defined as
confirmed plasma HIV-1 RNA > 50 copies/mL before or at Week 24